Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q1 FY2024 Earnings Presentation
17 slides from Alkem Laboratories's earnings presentation, Aug 10, 2023
Slide 1: Cover letter to stock exchanges on Q1FY24 results
<a> ALKEM ALKEM LABORATORIES LTD. Regd. OffJce : ALKEM HOUSE, Senapali Bapat Marg, Lower Pare) (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 10th August, 2023 To, The C
Slide 2: Press Release: Alkem reports Q1FY24 results
ALKEM LABORATORIES LTD. <8> ALKEM Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West) , Mumbai - 400 013, Maharashtra, India. • Phone: + 91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 Press Release Alkem repor
Slide 3: Operational Highlights
<a> ALKEM ALKEM LABORATORIES LTD. Regd. OffJce : ALKEM HOUSE, Senapali Bapat Marg, Lower Pare) (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 Operational Highlights Dome
Slide 4: R&D Investments
<a> ALKEM ALKEM LABORATORIES LTD. Regd. OffJce : ALKEM HOUSE, Senapali Bapat Marg, Lower Pare) (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 R&D Investments During the
Slide 5: Q1FY24 Conference Call
<a> ALKEM ALKEM LABORATORIES LTD. Regd. OffJce : ALKEM HOUSE, Senapali Bapat Marg, Lower Pare) (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 Q1FY24 Conference Call at 4
Slide 6: Investor Presentation Q1FY24
Investor Presentation Q1FY24 August 10, 2023
Slide 7: Safe Harbor Statement
Safe Harbor Statement <a> ALKEM This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assump
Slide 8: Key Highlights of Q1FY24
Key Highlights of Q1FY24 <a> ALKEM • Revenue from Operation grew by 15.2% YoY during the quarter, with EBITDA margin of 13.1% and Net Profit margin of 9.7% • India Business: As per IQVIA, Company’s sales in Q1FY24 registered growth of 7.6% compared to IPM growth of 8.5% • During the quarter, the com
Slide 9: Key Financial Highlights – Q1FY24 (Consolidated)
Key Financial Highlights – Q1FY24 (Consolidated) All figures in ₹ mn Revenue from Operations India sales 19,007 17,815 29,677 25,764 Q1FY23 Q1FY24 International sales 10,146 7,604 Q1FY23 Q1FY24 Q1FY23 Q1FY24
Slide 10: Key Financial Highlights – Q1FY24 (Consolidated)
Key Financial Highlights – Q1FY24 (Consolidated) <a> ALKEM All figures in ₹ mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 3,892 17,692 14,810 2,032 57.5% 59.6% 7.9% 13.1% Q1FY23 Q1FY24 Q1FY23 Q1FY24 PBT PAT (after Minority Interest) 2,867 3,529 1,276 1,519 Q1FY23 Q1FY24 Q1FY23 Q1FY24
Slide 11: India Business
India Business India Business: Q1FY24 Sales of ₹ 19,007 million (6.7% YoY growth) • India sales contributed 65.2% to total sales in Q1FY24 • As per IQVIA, In Q1FY24, the Company’s secondary sales grew by 7.6% compared to IPM growth of 8.5% YoY. • Due to delayed onset of monsoon, acute therapies grew
Slide 12: Secondary Sales Performance
Secondary Sales Performance <a> ALKEM Mixed growth across all major therapeutic segments in Q1FY24 Market rank 1 3 3 2 Acute Therapies Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients 10.5% 10.1% 9.8% 6.4% 4.9% 5.6% 4.0% 4.0% - Alkem sales growth YoY1,2 - Indian phar
Slide 13: US Business
US Business US Business: Q1FY24 Sales of ₹ 6,955 million (25.0% YoY growth) • US sales contributed 23.9% to total sales in Q1FY24 • During the quarter, the US business registered strong growth of 25.0% YoY and 17.5% QoQ. • In Q1FY24, the Company filed 1 ANDAs with the US FDA and received 7 approvals
Slide 14: US Business: Update on US FDA inspections
US Business <a> ALKEM Update on US FDA inspections Facility Capability Last inspection Status post last inspection Ankleshwar (India) API April 2023 Inspection is closed. EIR# received in July 2023 St. Louis (US) Formulations November 2022 Inspection is closed. EIR# received in December 2022 Bioequi
Slide 15: Other International Business
<a> Other International Business ALKEM Other International Business: Q1FY24 Sales of ₹ 3,191 million (56.5% YoY growth) • Other International Market sales contributed 10.9 % to total sales in Q1FY24 • The Company has presence mainly in Latin America, Australia, Europe, South East Asia, Africa and CI
Slide 16: Latest Shareholding Pattern
Latest Shareholding Pattern <a> ALKEM Shareholding pattern as on June 30, 2023 Non-Institution, 20.86% Promoter & Promoter Group, 57.16% Institution, 21.98% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, O
Slide 17: Thank You
<a> ALKEM Thank You For further information or queries, please contact Amit Kumar Khandelia VP Finance Tel: +91 22 3982 9999 E-mail: amit.khandelia@alkem.com